FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer

Colorectal cancer (CRC) is one of the top three malignant tumors in terms of morbidity, and the limited efficacy of existing therapies urges the discovery of potential treatment strategies. Immunotherapy gradually becomes a promising cancer treatment method in recent decades; however, less than 10%...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Lu, Jiang, Yi-Xin, Liu, Xiao-Xia, Jin, Jin-Mei, Gu, Wen-Jie, Luan, Xin, Guan, Ying-Yun, Zhang, Li-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228418/
https://www.ncbi.nlm.nih.gov/pubmed/37261088
http://dx.doi.org/10.1080/2162402X.2023.2217024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228418/
https://www.ncbi.nlm.nih.gov/pubmed/37261088
http://dx.doi.org/10.1080/2162402X.2023.2217024

Ejemplares similares